Iradimed Corporation reported a record fourth quarter and full year of 2025, driven by strong revenue growth and increased earnings. The company also announced a dividend increase, reflecting confidence in its business outlook and continued focus on innovation and operational efficiency.
Reported record revenue of $22.7 million for the fourth quarter of 2025, an increase of 17% year-over-year.
positiveReported record GAAP diluted EPS of $0.50 and non-GAAP diluted EPS of $0.54 for the fourth quarter of 2025, up 25% and 23% respectively year-over-year.
positiveReported record GAAP diluted EPS of $1.75 and non-GAAP diluted EPS of $1.93 for the full year of 2025, up 17% and 16% respectively year-over-year.
positiveIncreased regular quarterly cash dividend to $0.20 per share from $0.17 per share.
positiveGross profit margin for the fourth quarter was 75%, compared to 76% in the prior year period.
neutralGross profit margin for the full year was constant at approximately 77% for both 2025 and 2024.
neutralCash flow from operations for the three months ended December 31, 2025, was $5.9 million, compared to $6.0 million for the three months ended December 31, 2024, a decrease of 2%.
attentionCash flow from operations for the year ended December 31, 2025, was $24.9 million, compared to $25.6 million for the year ended December 31, 2024, a decrease of 3%.
attentionInventory purchases ahead of the Model 3870 launch negatively impacted cash flow from operations for the full year 2025.
attentionDomestic sales represented 81% of total revenue in Q4 2025, down from 85% in Q4 2024.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
MRI Compatible IV Infusion Pump Systems | N/A | — | — | — |
MRI Compatible Patient Vital Signs Monitoring Systems | N/A | — | — | — |
Ferro Magnetic Detection Systems | N/A | — | — | — |
Amortization of extended maintenance agreements | N/A | — | — | — |
Disposables | N/A | — | — | — |
Services and other | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Eighteenth consecutive quarter of record revenue, achieving $22.7 million in the fourth quarter of 2025—a 17% increase year-over-year and exceeding previously announced guidance.
Successfully shipped the initial 3870 units in the fourth quarter of 2025 as planned, marking a key milestone in our product roadmap. The full rollout of the next-generation 3870 MRI-compatible IV infusion pump is expected to begin in the first quarter of 2026, with real acceleration and meaningful revenue contribution expected in the second half of the year.
Accomplishments were made possible by the exceptional dedication and hard work of our employees, who tirelessly worked to clear the FDA 510k requirements and seamlessly navigated the transition to our new Orlando facility earlier in 2025, while maintaining operational excellence and supporting this important launch.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.